ankylosing spondylitis

Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Gilead, Galapagos clear another PhII hurdle for filgotinib, but can they hope to catch up with Novartis’ Cosentyx?
Endpoints
Gilead Sciences
Galapagos
filgotinib
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Izana starts proof-of-concept trial for spinal arthritis drug
Izana starts proof-of-concept trial for spinal arthritis drug
Fierce Biotech
Izana
clinical trials
namilumab
ankylosing spondylitis
Flag link:
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Pharmaforum
Novartis
Cosentyx
ankylosing spondylitis
Flag link:
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race
Endpoints
Eli Lilly
Taltz
Novartis
ankylosing spondylitis
Cosentyx
Flag link:
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis
Flag link:
Novartis strengthens autoimmune indications for Cosentyx
Novartis strengthens autoimmune indications for Cosentyx
PM Live
Novartis
Cosentyx
autoimmune disease
psoriatic arthritis
ankylosing spondylitis
Flag link:
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis
Novartis' Cosentyx racks up more long-term data in psoriatic arthritis and ankylosing spondylitis
Fierce Pharma
Novartis
Cosentyx
psoriatic arthritis
ankylosing spondylitis
Flag link:
Novartis' psoriasis mega-blockbuster hopeful Cosentyx nabs 2 new indications
Novartis' psoriasis mega-blockbuster hopeful Cosentyx nabs 2 new indications
BioPharma Dive
Novartis
Cosentyx
psoriasis
psoriatic arthritis
ankylosing spondylitis
Flag link:
Novartis’s Cosentyx: Europe’s First IL-17A Inhibitor for Some Uses
Novartis’s Cosentyx: Europe’s First IL-17A Inhibitor for Some Uses
Yahoo/Market Realist
Novartis
Cosentyx
Europe
ankylosing spondylitis
psoriatic arthritis
Flag link:
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, too
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, too
Fierce Pharma
Pfizer
Xeljanz
psoriasis
ankylosing spondylitis
Chron's Disease
Flag link:
Novartis wins European recs for a pair of new Cosentyx uses
Novartis wins European recs for a pair of new Cosentyx uses
Fierce Pharma
Novartis
Europe
Cosentyx
psoriatic arthritis
ankylosing spondylitis
Flag link:
Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis
Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis
Fierce Pharma
JNJ
Stelara
Novartis
ankylosing spondylitis
Flag link:
Novartis Announces Positive Phase-III Results For Secukinumab
Novartis Announces Positive Phase-III Results For Secukinumab
Bidness Etc.
Novartis
secukinumab
ankylosing spondylitis
Flag link:
Celgene spondylitis drug misses main goal in late-stage study
Celgene spondylitis drug misses main goal in late-stage study
Yahoo/Reuters
Celgene
ankylosing spondylitis
Otezla
Flag link:
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Yahoo
Regeneron
Sanofi
Sarilumab
rheumatoid arthritis
ankylosing spondylitis
Flag link: